Personalis's MRD momentum validated at $1.5B acquisition price; deal closing conditions determine whether shareholders capture that value

Personalis is a commercial-stage diagnostics company with an ultrasensitive blood test for detecting minimal residual disease in cancer patients, which is not yet approved for clinical use.

Tempus AI agreed to acquire Personalis for $1.5 billion, offering $16.25 per share in a deal that monetizes the NeXT Personal ultrasensitive MRD platform as a commercial asset. The thesis resolves entirely on whether the merger closes: shareholder approval, S-4 effectiveness, Nasdaq listing, and antitrust clearance must all clear by April 2027. The structural risk is deal-specific, as the all-stock consideration ties realized value to Tempus share price, with Personalis stockholders exposed to Tempus equity performance between signing and close.